TOKYO--(BUSINESS WIRE)--Treating male urethral stricture with the patient’s own buccal mucosal cells, encapsulated in a polymer scaffold as carrier, has been granted a patent in Japan. A longer ...

Guidelines for male urethral stricture The guidelines provide a clinical framework for the diagnosis and treatment of male urethral stricture. A clinical framework to guide providers in the diagnosis ...

Urethral stricture disease, characterised by narrowing of the urethral lumen, arises chiefly from trauma, infection or idiopathic scarring within the corpus spongiosum. Initial assessment combines ...

The FDA has granted approval to Urotronic Inc. for its Optilume urethral drug-coated balloon (DCB) for the treatment of male urethral strictures. The device inhibits new scar tissue growth that may ...

Urethral strictures refer to the narrowing of the urethra, which is the tube that carries urine out of the body. This condition is typically caused by scarring, which can block or narrow the urethra, ...

As judged from his history, the patient initially appeared to have acute kidney injury (AKI) that was due to lower urinary tract obstruction, resulting in urinary retention with overflow incontinence.

Treating male urethral stricture with the patient’s own buccal mucosal cells, encapsulated in a polymer scaffold as carrier, has been granted a patent in Japan. A longer duration of relief to patients ...

Source: Getty Images In a cohort study, 7% of patients had life-threatening complications associated with urethral stricture. Certain patients have an increased risk for complications from urethral ...

The Optilume device includes a balloon coated with paclitaxel. The Food and Drug Administration (FDA) has approved the Optilume ® Urethral Drug Coated Balloon (DCB) to treat patients with obstructive ...

TOKYO--(BUSINESS WIRE)--A novel and relatively pain-less treatment method for male urethral stricture using patients own buccal mucosal cells has been reported as successful in four out of six ...